Training Mode is OFF:
Home About Support Solutions Cases
Case Manager
Your browser may not be compatible with the full-featured viewer. Please consider switching to a recent version of Internet Explorer or Firefox.
You are currently viewing the basic HTML viewer. You can try the full viewer but some functionality may not work.
previously visited 10 YEAR OLD MALE. H/O UTI'S Random Case
Authored By: Faculty and residents Children's Hospital, Radiologist, Children's Health System, Birmingham, Alabama., USA.
Patient: 10 year old male
History:

10 yo male presented initally in 12/05 and 1st VCUG was done.

U/S done 4/06

Repeat VCUG in 6/06.

Images:[small]mediumlargeas-submittedimages only

Fig. 1: 12/05

Fig. 2: 12/05

Fig. 3: 4/06

Fig. 4: 6/06

Fig. 5: 6/06

Fig. 6: 6/06

Fig. 7: 6/06

Fig. 8: 6/06
Images:[small]mediumlargeas-submittedimages only
Findings:

VCUG in 12/05 Demonstrates b/l reflux grade 4 on Lt and grade 3-4 on rt

Bladder U/S in 4/06 shows hyperechoic foci at the bladder base B/L.

Repeat VCUG in 6/06 shows a posterior filling defect at the bladder base and complete resolution of the reflux.


What happened in the Interim????

Diagnosis: Severe reflux in 12/05 treated with Deflux procedure which causes the features seen on u/s and on VCUG in 4/06 and 6/06.
Discussion:

The hyperechoic lesions at the bladder base on the U/S represent subureteric chondrocyte mounds formed secondary to the deflux procedure. They may be multilobed or unilobed.

The absence of a subureteric chondrocyte mound or the presence of a multilobed mound contour is associated with persistent reflux.

More on the Deflux procedure:
In late 2001, the FDA approved a dextranomer/hyaluronic acid copolymer (Deflux), made of dextranomer microspheres (80–250 nm) that are suspended in a gel of non-animal stabilized hyaluronic acid for use in Grade II through IV VUR in children older than one year of age. The copolymer has been used in Europe since 1998. Both of these substances are polysaccharides, and the non-animal stabilized hyaluronic acid is very similar to the natural hyaluronic acid found in the body. Dextranomer and hyaluronic acid are biodegradable and lack allergenic or immunogenic properties.

During an endoscopic procedure, Deflux is injected into the submucosal area next to the ureter-bladder junction. At this point at the junction, the substance forms a one-way valve, overcoming the backflow pressure from the bladder. The dextranomer facilitates the growth of fibroblasts and collagen between the microspheres as the hyaluronic acid degrades. The artificial valve is consolidated with endogenous tissue that stabilizes the bulk effect for a sustained response.


Initial studies have demonstrated resolution rates of 66 percent to 77 percent. Depending on the grade and age of patient, this is approximately double the rate of resolution compared with antibiotic treatment and is nearly the same as open surgical treatment. Longer-term observation of patients demonstrated that as many as 96 percent of ureters that were free of grade III or greater reflux from three to twelve months after treatment were still free of reflux two to five years post-injection.

The retail cost of the material is $925 per vial, with one vial used for each ureter that is affected by reflux. The procedure is performed on an outpatient basis, with the patient given mild anesthesia and, barring complications, same-day discharge. This is much less expensive than the open surgical procedure, which requires several days in the hospital and exposes the child to all of the potential complications, such as scarring, infection, and prolonged recovery. In addition, the long term net cost is actually less than chronic antibiotic use.


References:

Harriet J. Paltiel, David A. Diamond, David Zurakowski, Laura A. Drubach, and Anthony Atala
Endoscopic Treatment of Vesicoureteral Reflux with Autologous Chondrocytes: Postoperative Sonographic Features
Radiology 2004 232: 390-397;


http://radiology.rsnajnls.org/cgi/content/full/232/2/390?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=deflux&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT


http://www.managedcaremag.com/archives/0310/0310.biotech.html

Comments: post a comment
No comments posted.
Additional Details:

Case Number: 5140252Last Updated: 06-28-2006
Rating:

0 ratings
Anatomy: Genitourinary (GU)   Pathology: Other
Modality: Conventional Radiograph, GU, USAccess Level: Readable by all users

Case has been viewed 818 times.

User Guide Terms Site Map Contact Us
Powered by Horizon Study Share.   Copyright © 2009 McKesson Corporation and/or one of its subsidiaries.
Horizon Study Share is a trademark of McKesson Information Solutions LLC.


Users are fully responsible for the content of each case that they post. Text and images may be copyrighted by the case author or institution. McKesson Corp. is not responsible for any content herein, and in no way vouches for its accuracy or appropriateness. It is a violation of the user agreement to post identifiable patient information or inappropriate content. If you notice a case which is in violation of policy, please alert us using our contact form. This system is not a medical device, and is intended to be used for educational and reference purposes only. By using this system, you agree to abide by the terms and conditions of use, which precludes using this system for the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in humans or animals.